Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397240 | 1.00 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL30405284 | 1.00 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16095047 | 0.96 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16121460 | 0.96 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16094264 | 0.95 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL22473686 | 0.95 | RAF1 (0.91) | RAF1BRAF | |
| SCHEMBL17503437 | 0.95 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL17523473 | 0.95 | RAF1 (0.91) | RAF1BRAF | |
| SCHEMBL16121218 | 0.95 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL29308909 | 0.95 | RAF1 (0.90) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250108055-A1 | COMBINATION THERAPIES | MIRATI THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12208099-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-12036227-B2 | Combination therapy | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12036227-B2 | Combination therapy | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12036227-B2 | Combination therapy | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| WO-2024138206-A1 | FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208099-B2 | Combination therapies | KRAS, NRAS, HRAS | RAF1 5/4885BRAF 4/4885 |
| US-20250108055-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | RAF1 5/4885BRAF 4/4885 |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | KRAS, HRAS, TP53 | RAF1 45/4885BRAF 14/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RAF1 18/4885BRAF 16/4885 |
| US-12036227-B2 | Combination therapy | BRAF, NRAS, RAF1 | RAF1 3/4885BRAF 1/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RAF1 18/4885BRAF 16/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.